Opioid regulations, scrutiny featured in CDA Journal

In collaboration with pharmacy colleagues, authors of the November issue of the Journal of the California Dental Association present the most current information on pain management in dentistry. This issue includes timely information relative to opioid medication regulations and abuse. With growing scrutiny and regulations on the drugs used for pain management, both are important considerations that dentists and pharmacists are increasingly required to keep in mind.

Topics include:

  • Evidence-based pharmacologic approaches for chronic orofacial pain.
  • Changing paradigms for acute dental pain and how prevention is better than PRN.
  • Dietary supplements and alternative therapies for pain management.
  • A new paradigm for providers: dentists and pharmacists.
  • Combating an epidemic of prescription opioid abuse.

To view additional content on prescription drug abuse, download the ePub Journal on a mobile device. Watch an embedded video of pharmacy experts discussing the use of opioids in society and how prescribers have a role in recognizing the problem of controlled substance abuse, consulting with primary care physicians and understanding the pharmaceutical options for pain control.

Download the ePub Journal (and CDA Update) at cda.org/apps. The ePub is delivered to mobile devices each month and includes dynamic interactivity, such as embedded videos and one-click Web and email links for more information, as well as the ability to "clip" an article or photo and share it through social media or email.

For more information on controlled substance abuse, regulations and the role of prescribers in recognizing and preventing abuse, read the "Role of dentists in reducing prescription drug abuse."

Related Items

The CURES enrollment deadline for providers has officially been pushed back from Jan. 1 to July 1 of 2016. The change comes after the governor signed AB 679 (Allen). The bill was amended late in the legislative session due to concern that the most recent Controlled Substance Utilization Review and Evaluation System (CURES) update has fallen behind schedule. The CURES 2.0 was planned to be in use by July 1 of this year, yet the system is still not fully operational. The delay will give the Department of Justice (DOJ) time to finalize CURES 2.0 and for providers to enroll.

In California, more than 1 billion dosage units of hydrocodone combination products were dispensed in the 2013-14 fiscal year, according to the state’s Controlled Substance Utilization Review and Evaluation System (CURES). What's more, approximately 100 percent of the hydrocodone use worldwide occurs in the U.S., according to Tony J. Park, PharmD, JD, who co-hosted a lecture on the topic at CDA Presents The Art and Science of Dentistry in Anaheim on May 2.